ChemGenex Pharmaceuticals

ChemGenex Pharmaceuticals is a drug discovery and development company. ChemGenex is based in Geelong and Menlo Park, California. The Chief Executive of ChemGenex, Professor Greg Collier is a former Alfred Deakin Professor at Deakin University.

ChemGenex Pharmaceuticals Limited is a public company working to develop targeted medicines for the treatment of cancer. By focusing on validated targets in diseases with genetic components, ChemGenex seeks to bring targeted therapeutics to market that address chronic diseases with high unmet medical need. The company's clinical pipeline of cancer drugs provide a solid foundation to meet these objectives.

ChemGenex's most advanced product candidate, Omacetaxine mepsuccinate, is currently completing registration-directed trials to treat the growing number of CML patients who are resistant to tyrosine kinase inhibitor therapy. 

For further information on ChemGenex Pharmaceuticals please visit: www.chemgenex.com